secwatch.observer — SEC 8-K summary
======================================

Issuer:     Absci Corp (ABSI)
CIK:        0001672688
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001628280-23-038977
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Absci partners with Almirall (up to $664M deal) and reports Q3 net loss of $22M
-------------------------------------------------------------------------------

- Entered AI drug partnership with Almirall for dermatology; up to $664M in milestones plus royalties for two programs.
- Q3 revenue fell to $0.7M from $2.4M YoY; net loss narrowed to $22.0M from $27.3M.
- Unveiled four wholly-owned AI drug assets (cytokine biology); first IND filing expected early 2025.
- Cash, equivalents, and short-term investments $113.5M; cash runway into late 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023038977/0001628280-23-038977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672688/000162828023038977/absc-20231114.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer